Global Tenofovir Disoproxil Fumarate Market report offers deep insights into the key market segments by regions, market status, key industry players, growth, size, opportunities, and forecast.
Tenofovir Disoproxil Fumarate (Tenofovir DF) is a prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of HIV infection in adults and children 2 years of age and older who weigh at least 22 lb (10 kg), according to Clinical Info. Tenofovir DF is always recommended along with other HIV medicines.
Clinical Info is an informational website that offers access to the latest, federally approved HIV/AIDS medical practice guidelines.
HIV medications do not cure HIV/AIDS, but it is important to take them in order to control the infection so one can live a longer, healthier life. In addition, HIV medications reduce the risk of HIV transmission. One should continue taking HIV medicines unless their medical provider tells otherwise.
Tenofovir DF has also been approved for the treatment of chronic hepatitis B virus infection (HBV) in adults and children 2 years of age and older who weigh at least 22 lb (10 kg), according to Clinical Info.
The Global Tenofovir Disoproxil Fumarate Market report is an integrated document that delivers a detailed analysis of the industry.
The report, available at Market Study Report, also contains an in-depth outline of the business in tandem with its market size and status.
The Global Tenofovir Disoproxil Fumarate market report presents a full breakdown of key players, such as Glaxo SmithKline, Gilead Sciences, PHARMACARE, Cipla, Zydus Cadila, Dr. Reddy’s Laboratories, Mylan Pharmaceuticals, Natco Pharma, Emcure Pharmaceuticals, Torrent Pharmaceuticals, among others.
The market segmentation includes North America, South America, Asia-Pacific, Europe, the Middle East, and Africa. The Global Tenofovir Disoproxil Fumarate market report also contains the forecast prediction pertaining to the growth of the industry in the next five years.
